Farletuzumab (MORAb-003) is a FRα-targeting mAb tested in combination with standard platinum-based chemotherapy in patients with relapsed platinum-sensitive ovarian cancer patients in a Phase 3 clinical trial. This evidence concerns the gene FOLR1 and ovarian cancer.